NGEN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NG

Mkt Cap

$170.6M

Volume

299.12K

Next Earnings

November 12th

Loading chart

NG

NGENNervGen Pharma Corp. Common stock

NGEN

Pay with—

Available Balance0.00

NG

Mkt Cap

$174.2M

Volume

299.12K

Next Earnings

November 12th

Chart Earnings News About Insider Filings

NervGen Announces Pricing of US$60.0 Million Public Offering of SecuritiesNervGen Pharma Corp. announced the pricing of an underwritten public offering of 24 million common shares at US$2.50 per share, along with accompanying warrants at an exercise price of US$3.68, expected to raise approximately US$60 million in gross proceeds. The company plans to use the net proceeds to advance its lead therapeutic candidate NVG-291 through clinical studies. The offering is expected to close on May 26, 2026, with Leerink Partners and TD Cowen serving as joint bookrunning managers.GlobeNewswire Inc. · May 22, 2026

The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsightThe spinal cord injury treatment market is experiencing significant expansion with multiple emerging therapies in development. Currently valued at USD 354 million in 2025, the market is projected to grow to USD 1.4 billion by 2034 at a 15.4% CAGR. Six key therapies are highlighted: KP-100IT (hepatocyte growth factor), Neuro-Cells (stem cell therapy), MT-3921 (RGMa inhibitor), Elezanumab (RGMa inhibitor), NFX88 (neuropathic pain relief), and NVG-291 (neurorepair peptide). These innovations address a critical unmet medical need, as STEMIRAC remains the only approved disease-modifying treatment, available exclusively in Japan.GlobeNewswire Inc. · Apr 2, 2026

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord InjuryNervGen Pharma announced the appointment of Adam Rogers, MD as President and Chief Executive Officer, effective immediately. Rogers, who previously served as Interim CEO and Chairman, led the company through its recent Nasdaq listing. The appointment reflects the Board's confidence in his execution of key milestones and his vision to advance NVG-291, the company's lead neuroreparative therapeutic candidate for spinal cord injury treatment.GlobeNewswire Inc. · Feb 9, 2026

to start trading

NG

NGENNervGen Pharma Corp. Common stock

NGEN

Pay with—

Available Balance0.00

Your PositionYou don't own any NGEN yet.

Related Tickers

Earnings